​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals (RYTM) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $141.33, with a high of $155.00 and a low of $125.00. This represents a 38.42% increase from the last price of $102.10.

- $40 $80 $120 $160 $200 High: $155 Avg: $141.33 Low: $125 Last Closed Price: $102.1

RYTM Stock Rating

Rhythm Pharmaceuticals stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 0 21 Strong Sell Sell Hold Buy Strong Buy

RYTM Price Target Upside V Benchmarks

TypeNameUpside
StockRhythm Pharmaceuticals38.42%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1522
Avg Price Target$141.00$144.60$137.27
Last Closing Price$102.10$102.10$102.10
Upside/Downside38.10%41.63%34.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 264111--16
Jun, 264111--16
May, 264111--16
Apr, 264111--16
Mar, 264111--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 07, 2026RBC Capital$141.00$111.6826.25%38.10%
Jun 16, 2026Whitney IjemCanaccord Genuity$151.00$89.7068.34%47.89%
Jun 15, 2026Paul MatteisStifel Nicolaus$133.00$94.7340.40%30.26%
Jun 15, 2026Wells Fargo$155.00$88.3875.38%51.81%
May 07, 2026Canaccord Genuity$143.00$96.6148.02%40.06%
Mar 12, 2026Wells Fargo$143.00$90.0258.85%40.06%
Mar 03, 2026Dennis DingJefferies$125.00$89.5639.57%22.43%
Feb 26, 2026Paul MatteisStifel Nicolaus$131.00$99.5431.61%28.31%
Feb 18, 2026Lisa WalterRBC Capital$145.00$101.3043.14%42.02%
Jan 20, 2026H.C. Wainwright$125.00$101.6323.00%22.43%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 07, 2026RBC CapitalOutperformOutperformhold
Jun 17, 2026Cowen & Co.BuyBuyhold
Jun 15, 2026Wells FargoOverweightOverweighthold
Jun 03, 2026CitigroupMarket OutperformMarket Outperformhold
Mar 12, 2026Wells FargoOverweightOverweighthold
Mar 03, 2026JefferiesBuyBuyhold
Feb 18, 2026RBC CapitalOutperforminitialise
Jan 20, 2026H.C. WainwrightBuyBuyhold
Jan 20, 2026Wells FargoOverweightOverweighthold
Dec 22, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.37$-3.51$-3.20$-4.34$-3.11---
Avg Forecast$-1.45$-3.53$-3.20$-4.12$-2.46$-0.75$2.25$6.28
High Forecast$-1.28$-3.23$-3.16$-3.82$-1.98$0.06$2.74$7.69
Low Forecast$-1.70$-4.09$-3.27$-4.39$-2.79$-2.04$1.22$5.49
Surprise %-5.52%-0.57%-5.34%26.42%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.15M$23.64M$77.43M$130.13M$189.76M---
Avg Forecast$3.03M$21.41M$78.80M$126.00M$181.85M$333.83M$602.63M$970.38M
High Forecast$3.44M$23.99M$80.69M$127.08M$208.91M$333.83M$602.63M$1.14B
Low Forecast$2.76M$20.00M$77.29M$125.06M$164.87M$333.83M$602.63M$876.95M
Surprise %4.19%10.43%-1.75%3.27%4.35%---

Net Income Forecast

$-300M $-150M $0 $150M $300M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-69.61M$-181.12M$-184.68M$-260.60M$-201.92M---
Avg Forecast$-83.43M$-203.78M$-184.68M$-236.88M$-137.49M$-42.97M$114.18M$362.02M
High Forecast$-73.77M$-186.37M$-182.31M$-220.43M$-113.92M$3.61M$158.06M$443.67M
Low Forecast$-98.19M$-235.71M$-188.66M$-253.33M$-161.06M$-117.89M$70.31M$316.71M
Surprise %-16.57%-11.12%-10.02%46.86%---

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals stock a buy?

Rhythm Pharmaceuticals stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rhythm Pharmaceuticals is a favorable investment for most analysts.

What is Rhythm Pharmaceuticals's price target?

Rhythm Pharmaceuticals's price target, set by 21 Wall Street analysts, averages $141.33 over the next 12 months. The price target range spans from $125 at the low end to $155 at the high end, suggesting a potential 38.42% change from the previous closing price of $102.1.

How does Rhythm Pharmaceuticals stock forecast compare to its benchmarks?

Rhythm Pharmaceuticals's stock forecast shows a 38.42% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rhythm Pharmaceuticals over the past three months?

  • July 2026: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.

What is Rhythm Pharmaceuticals’s EPS forecast?

Rhythm Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.75, marking a -75.88% decrease from the reported $-3.11 in 2025. Estimates for the following years are $2.25 in 2027, and $6.28 in 2028.

What is Rhythm Pharmaceuticals’s revenue forecast?

Rhythm Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $333.83M, reflecting a 75.92% increase from the reported $189.76M in 2025. The forecast for 2027 is $602.63M, and $970.38M for 2028.

What is Rhythm Pharmaceuticals’s net income forecast?

Rhythm Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-42.973M, representing a -78.72% decrease from the reported $-202M in 2025. Projections indicate $114.18M in 2027, and $362.02M in 2028.